Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Curis (CRIS – Research Report), Health Catalyst (HCAT – Research Report) and Innate Pharma SA (IPHYF – Research Report).

Curis (CRIS)

In a report released yesterday, Soumit Roy from JonesTrading reiterated a Buy rating on Curis, with a price target of $18.00. The company’s shares closed last Tuesday at $15.69.

According to TipRanks.com, Roy has 0 stars on 0-5 stars ranking scale with an average return of -7.2% and a 27.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Acrivon Therapeutics, Inc., and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Curis with a $23.33 average price target, which is a 48.3% upside from current levels. In a report issued on May 8, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Health Catalyst (HCAT)

RBC Capital analyst Sean Dodge maintained a Hold rating on Health Catalyst on May 10 and set a price target of $8.00. The company’s shares closed last Tuesday at $6.84, close to its 52-week low of $5.45.

According to TipRanks.com, Dodge has 0 stars on 0-5 stars ranking scale with an average return of -7.5% and a 37.7% success rate. Dodge covers the Healthcare sector, focusing on stocks such as Privia Health Group, Healthcare Services, and Avid Bioservices.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Health Catalyst with a $11.88 average price target, implying a 72.2% upside from current levels. In a report issued on May 10, KeyBanc also maintained a Hold rating on the stock.

Innate Pharma SA (IPHYF)

In a report issued on May 13, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA, with a price target of EUR3.10. The company’s shares closed last Wednesday at $2.20, close to its 52-week low of $2.13.

According to TipRanks.com, Telliez is ranked #8047 out of 8841 analysts.

Innate Pharma SA has an analyst consensus of Hold, with a price target consensus of $3.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CRIS:

• Curis Inc Showcases Leukemia Study Breakthroughs at Conferences
• Curis Inc. Insiders Hold Steady: No New Trades Signal Confidence or Complacency?
• Curis price target raised to $27 from $15 at JonesResearch
• Curis Provides First Quarter 2024 Business Update
• Curis reports Q1 EPS ($2.05), consensus ($2.12)